The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
 
Thomas J. Herzog
Leadership - GOG Partners
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Roche/Genentech
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Alkermes (Inst); Aravive; AstraZeneca; Blueprint Medicines (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); I-Mab (Inst); Immunogen; InxMed (Inst); Merck; Mereo BioPharma; Mereo BioPharma (Inst); Mersana (Inst); Myriad Genetics; Novartis; Onconova Therapeutics; OncXerna Therapeutics; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Forty Seven (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - GOG Partners (Inst)
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer; Kadmon; Merck; Mersana; Pfizer/EMD Serono; Repare Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); tesaro (Inst)
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
John L. Hays
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Ipsen; Merck; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Merck; Tesaro
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro
 
Joyce N. Barlin
Honoraria - AstraZeneca/Merck; Merck
Consulting or Advisory Role - Clovis Oncology
Speakers' Bureau - AstraZeneca/Merck; Merck
 
Julie R. Graham
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Monali Desai, MD
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Yan Wang
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Yangchun Du
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Rita P. Dalal
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group